Copyright
©The Author(s) 2018.
World J Gastroenterol. Feb 14, 2018; 24(6): 725-736
Published online Feb 14, 2018. doi: 10.3748/wjg.v24.i6.725
Published online Feb 14, 2018. doi: 10.3748/wjg.v24.i6.725
Characteristics | Total (n = 211) | HBeAg-positive (n = 62) | HBeAg-negative (n = 149) | P value1 |
Age (yr) | 50.4 ± 11.9 | 43.8 ± 12.2 | 53.2 ± 10.6 | < 0.0001 |
Male | 147 (69.7) | 39 (63.0) | 108 (72.5) | 0.170 |
Treatment time (yr) | 5.24 (2.00-9.62) | 4.39 (2.11-9.62) | 5.35 (2.00-9.58) | 0.590 |
Cirrhosis | 66 (31.3) | 12 (19.4) | 54 (36.2) | 0.016 |
HCC2 | 32 (15.2) | 5 (8.1) | 27 (18.1) | 0.060 |
HBV genotype3 | 101:86:2 (53.4%:45.5%:1.1%) | 21:39:01 | 80:47:01 | 0.001 |
B:C:B + C | (34.4%:63.9%:1.6%) | (62.5%:36.7%:0.8%) | ||
ALT (× ULN) | 4.12 ± 5.88 | 4.42 ± 6.62 | 3.99 ± 5.56 | 0.630 |
HBV DNA (log IU/mL) | 5.84 ± 1.70 | 7.24 ± 1.39 | 5.26 ± 1.50 | < 0.0001 |
HBsAg (log IU/mL) | 3.15 ± 0.80 | 3.80 ± 0.71 | 2.89 ± 0.67 | < 0.0001 |
- Citation: Lin TC, Chiu YC, Chiu HC, Liu WC, Cheng PN, Chen CY, Chang TT, Wu IC. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy. World J Gastroenterol 2018; 24(6): 725-736
- URL: https://www.wjgnet.com/1007-9327/full/v24/i6/725.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i6.725